Japan · Delayed Price · Currency is JPY Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 2.89 trillion. The enterprise value is 3.57 trillion.
| Market Cap | 2.89T |
| Enterprise Value | 3.57T |
Important Dates
The last earnings date was Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -0.11% in one year.
| Current Share Class | 1.79B |
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | -0.11% |
| Shares Change (QoQ) | -1.26% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 53.91% |
| Float | 1.75B |
Valuation Ratios
The trailing PE ratio is 35.59 and the forward PE ratio is 18.01. Astellas Pharma's PEG ratio is 0.40.
| PE Ratio | 35.59 |
| Forward PE | 18.01 |
| PS Ratio | 1.49 |
| PB Ratio | 1.95 |
| P/TBV Ratio | 67.89 |
| P/FCF Ratio | 14.39 |
| P/OCF Ratio | 12.22 |
| PEG Ratio | 0.40 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.40, with an EV/FCF ratio of 17.75.
| EV / Earnings | 43.72 |
| EV / Sales | 1.83 |
| EV / EBITDA | 7.40 |
| EV / EBIT | 12.51 |
| EV / FCF | 17.75 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.17 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 1.83 |
| Debt / FCF | 4.43 |
| Interest Coverage | 15.13 |
Financial Efficiency
Return on equity (ROE) is 5.17% and return on invested capital (ROIC) is 7.16%.
| Return on Equity (ROE) | 5.17% |
| Return on Assets (ROA) | 5.10% |
| Return on Invested Capital (ROIC) | 7.16% |
| Return on Capital Employed (ROCE) | 12.96% |
| Revenue Per Employee | 142.56M |
| Profits Per Employee | 5.98M |
| Employee Count | 13,643 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.26 |
Taxes
| Income Tax | -10.41B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.61% in the last 52 weeks. The beta is 0.12, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | -4.61% |
| 50-Day Moving Average | 1,437.92 |
| 200-Day Moving Average | 1,490.24 |
| Relative Strength Index (RSI) | 75.29 |
| Average Volume (20 Days) | 8,535,230 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of JPY 1.94 trillion and earned 81.57 billion in profits. Earnings per share was 45.39.
| Revenue | 1.94T |
| Gross Profit | 1.59T |
| Operating Income | 288.77B |
| Pretax Income | 71.16B |
| Net Income | 81.57B |
| EBITDA | 485.44B |
| EBIT | 288.77B |
| Earnings Per Share (EPS) | 45.39 |
Balance Sheet
The company has 215.40 billion in cash and 889.49 billion in debt, giving a net cash position of -674.09 billion or -376.52 per share.
| Cash & Cash Equivalents | 215.40B |
| Total Debt | 889.49B |
| Net Cash | -674.09B |
| Net Cash Per Share | -376.52 |
| Equity (Book Value) | 1.48T |
| Book Value Per Share | 827.72 |
| Working Capital | 185.39B |
Cash Flow
In the last 12 months, operating cash flow was 236.75 billion and capital expenditures -35.81 billion, giving a free cash flow of 200.94 billion.
| Operating Cash Flow | 236.75B |
| Capital Expenditures | -35.81B |
| Free Cash Flow | 200.94B |
| FCF Per Share | 112.23 |
Margins
Gross margin is 81.86%, with operating and profit margins of 14.85% and 4.19%.
| Gross Margin | 81.86% |
| Operating Margin | 14.85% |
| Pretax Margin | 3.66% |
| Profit Margin | 4.19% |
| EBITDA Margin | 24.96% |
| EBIT Margin | 14.85% |
| FCF Margin | 10.33% |
Dividends & Yields
This stock pays an annual dividend of 78.00, which amounts to a dividend yield of 4.83%.
| Dividend Per Share | 78.00 |
| Dividend Yield | 4.83% |
| Dividend Growth (YoY) | 5.56% |
| Years of Dividend Growth | 9 |
| Payout Ratio | 162.41% |
| Buyback Yield | 0.11% |
| Shareholder Yield | 4.93% |
| Earnings Yield | 2.82% |
| FCF Yield | 6.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.
| Last Split Date | Mar 27, 2014 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Astellas Pharma has an Altman Z-Score of 2.15 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.15 |
| Piotroski F-Score | 7 |